Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

C. Taibi; M. Tempestilli; A. D'Avolio; A. R. Garbuglia; A. De Nicolò; M. Montalbano; G. D'Offizi

doi:10.1111/jcpt.12546

Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

C. Taibi, M. Tempestilli, A. D'Avolio, A. R. Garbuglia, A. De Nicolò, M. Montalbano, G. D'Offizi

Research output: Contribution to journal › Article › peer-review

Abstract

What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.

Original language	English
Pages (from-to)	621-623
Number of pages	3
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	42
Issue number	5
DOIs	https://doi.org/10.1111/jcpt.12546
Publication status	Published - Oct 1 2017

Keywords

gastrectomy
hepatitis C virus
ledipasvir
pharmacokinetics
sofosbuvir

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1111/jcpt.12546

Cite this

@article{4dae7430c13b4207be4b5e5bc7cf3a4b,

title = "Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient",

abstract = "What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.",

keywords = "gastrectomy, hepatitis C virus, ledipasvir, pharmacokinetics, sofosbuvir",

author = "C. Taibi and M. Tempestilli and A. D'Avolio and Garbuglia, {A. R.} and {De Nicol{\`o}}, A. and M. Montalbano and G. D'Offizi",

year = "2017",

month = oct,

day = "1",

doi = "10.1111/jcpt.12546",

language = "English",

volume = "42",

pages = "621--623",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

AU - Taibi, C.

AU - Tempestilli, M.

AU - D'Avolio, A.

AU - Garbuglia, A. R.

AU - De Nicolò, A.

AU - Montalbano, M.

AU - D'Offizi, G.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.

AB - What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.

KW - gastrectomy

KW - hepatitis C virus

KW - ledipasvir

KW - pharmacokinetics

KW - sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85018367711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018367711&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12546

DO - 10.1111/jcpt.12546

M3 - Article

AN - SCOPUS:85018367711

VL - 42

SP - 621

EP - 623

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 5

ER -

Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this